Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection

Final draft guidance: TA1043

Final draft guidance (PDF 231 KB)

Committee papers (PDF 1.1 MB)

Public committee slides (PDF 705 KB)

Draft guidance: TA1043

Draft guidance (downloadable version) (PDF 291 KB)

Draft guidance (online commenting)

Committee papers (PDF 8.15 MB)

Final scope (PDF 179 KB)

Final stakeholder list (PDF 118 KB)

NICE's response to comments on the draft scope and provisional stakeholder list (PDF 207 KB)

Draft scope post referral (PDF 187 KB)

Register of interests (PDF 150 KB)

Final draft guidance (PDF 254 KB)

Final draft guidance: Managed Access Agreement (PDF 393 KB)

Committee papers (PDF 1.51 MB)

Draft consultation document (downloadable version) (PDF 281 KB)

Committee papers (PDF 4.51 MB)

Final scope (PDF 183 KB)

Final stakeholder list (PDF 158 KB)

NICE's response to comments on the draft scope and provisional stakeholder list (PDF 263 KB)

Draft scope post referral (PDF 195 KB)